202 related articles for article (PubMed ID: 30604493)
1. One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis.
Rozemeijer R; van Muiden IG; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Doevendans PA; Voskuil M; Stella PR
Catheter Cardiovasc Interv; 2019 Jul; 94(1):61-69. PubMed ID: 30604493
[TBL] [Abstract][Full Text] [Related]
2. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
Rozemeijer R; Stein M; Voskuil M; van den Bor R; Frambach P; Pereira B; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Agostoni P; Roes KC; Doevendans PA; Stella PR;
Circulation; 2019 Jan; 139(1):67-77. PubMed ID: 30586704
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
4. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
5. 3-Year Clinical Outcomes After Implantation of Permanent-Polymer Versus Polymer-Free Stent: ReCre8 Landmark Analysis.
van Hemert ND; Voskuil M; Rozemeijer R; Stein M; Frambach P; Pereira B; Rittersma SZ; Kraaijeveld AO; Leenders GEH; Timmers L; van der Harst P; Agostoni P; Stella PR;
JACC Cardiovasc Interv; 2021 Nov; 14(22):2477-2486. PubMed ID: 34794654
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
7. One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis.
Wang H; Xie X; Zu Q; Lu M; Chen R; Yang Z; Gao Y
Cardiovasc Diabetol; 2022 Oct; 21(1):220. PubMed ID: 36307791
[TBL] [Abstract][Full Text] [Related]
8. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C
JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry.
Rozemeijer R; Benedetto D; Kraaijeveld AO; Voskuil M; Stein M; Timmers L; Rittersma SZ; Agostoni P; Doevendans PA; Stella PR
Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):521-525. PubMed ID: 29137966
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes after permanent polymer or polymer-free stent implantation in patients with diabetes mellitus: The ReCre8 diabetes substudy.
van Hemert ND; Rozemeijer R; Voskuil M; Stein M; Frambach P; Rittersma SZ; Kraaijeveld AO; Leenders GEH; van der Harst P; Agostoni P; Stella PR;
Catheter Cardiovasc Interv; 2022 Feb; 99(2):366-372. PubMed ID: 33811730
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of contemporary drug-eluting stent implantation in diabetic patients: Subanalysis of a randomized controlled trial.
van Hemert ND; Voskuil M; Rozemeijer R; Kraaijeveld AO; Rittersma SZ; Leenders GEH; Stein M; Frambach P; van der Harst P; Agostoni P; Stella PR;
Catheter Cardiovasc Interv; 2023 Feb; 101(3):505-510. PubMed ID: 36651339
[TBL] [Abstract][Full Text] [Related]
12. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents (ISAR-TEST 5) trial.
Koch T; Lenz T; Joner M; Xhepa E; Koppara T; Wiebe J; Coughlan JJ; Aytekin A; Ibrahim T; Kessler T; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Kufner S;
Clin Res Cardiol; 2021 Oct; 110(10):1586-1598. PubMed ID: 34156521
[TBL] [Abstract][Full Text] [Related]
13. Polymer-free amphilimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus.
Godino C; Pivato CA; Chiarito M; Donahue M; Testa L; Colantonio R; Cappelletti A; Milazzo D; Parisi R; Nicolino A; Moshiri S; Aprigliano G; Palloshi A; Zavalloni Parenti D; Rutigliano D; Locuratolo N; Melillo F; Scotti A; Arrigoni L; Montorfano M; Fattori R; Presbitero P; Sardella G; Bedogni F; Margonato A; Briguori C; Colombo A;
Int J Cardiol; 2017 Oct; 245():69-76. PubMed ID: 28874301
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of polymer-free biolimus-eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries.
D'Ascenzo F; Gaido L; Bernardi A; Saglietto A; Franzé A; Ielasi A; Trabattoni D; Di Biasi M; Infantino V; Rognoni A; Helft G; Gangor A; Latini RA; De Luca L; Mitomo S; Ugo F; Smolka G; Huczek Z; Cortese B; Capodanno D; Chieffo A; Piazza F; di Mario C; Poli A; D'Urbano M; Romeo F; Giammaria M; Varbella F; Sheiban I; Escaned J; De Ferrari GM
Catheter Cardiovasc Interv; 2020 Feb; 95(3):522-529. PubMed ID: 31385427
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes with reservoir-based polymer-free amphilimus-eluting stents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry.
Sardella G; Stella P; Chiarito M; Leone AM; Balian V; Prosperi F; Sorropago G; Mancone M; Calcagno S; Briguori C; Stefanini GG
Catheter Cardiovasc Interv; 2018 Apr; 91(5):884-891. PubMed ID: 28707375
[TBL] [Abstract][Full Text] [Related]
16. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
[TBL] [Abstract][Full Text] [Related]
17. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents.
Chandrasekhar J; Kok MM; Kalkman DN; Aquino MB; Zocca P; Woudstra P; Beijk MA; Kerkmeijer LS; Sartori S; Baber U; Tijssen JG; Koch KT; Dangas GD; Colombo A; Pocock S; von Birgelen C; Mehran R; de Winter RJ;
JACC Cardiovasc Interv; 2020 Apr; 13(7):820-830. PubMed ID: 32273094
[TBL] [Abstract][Full Text] [Related]
18. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
Kufner S; Sorges J; Mehilli J; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Rheude T; Ibrahim T; Massberg S; Laugwitz KL; Kastrati A; Byrne RA;
JACC Cardiovasc Interv; 2016 Apr; 9(8):784-792. PubMed ID: 27017366
[TBL] [Abstract][Full Text] [Related]
19. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
Colleran R; Kufner S; Harada Y; Giacoppo D; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Schneider S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
Catheter Cardiovasc Interv; 2017 Feb; 89(3):367-374. PubMed ID: 27377301
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of amphilimus sirolimus-eluting stents versus zotarolimus-eluting stents in all-comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial.
Rozemeijer R; Stein M; Frambach P; Voskuil M; Kraaijeveld AO; Rodríguez-Olivares R; Timmers L; Pereira B; Rittersma SZ; Agostoni P; Doevendans PA; Stella PR
Catheter Cardiovasc Interv; 2018 Feb; 91(3):410-416. PubMed ID: 28544782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
